TGFβ-activated SMAD2 acts as an important transcriptional factor in proinflammatory Th17 cells (7, 38, 46), which are abundant in patients with MS and further increase in number during relapses (38, 52). The gene discussed is TGFB1; the disease is myeloid sarcoma.